Comparative Pharmacology
Head-to-head clinical analysis: KEFLIN versus MAXIPIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLIN versus MAXIPIME.
KEFLIN vs MAXIPIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It has enhanced activity against Gram-negative bacteria due to rapid penetration through the outer membrane and low affinity for β-lactamases.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
1-2 g IV every 8-12 hours for most indications; maximum 2 g every 8 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Terminal elimination half-life is approximately 2-2.5 hours in adults with normal renal function; extends to 8-12 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 20-24 hours in severe impairment (CrCl < 30 mL/min).
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Primarily renal (approximately 80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (< 1%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic